Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome
Phase 2
Completed
- Conditions
- Insulin Resistance Syndrome
- Registration Number
- NCT03741686
- Lead Sponsor
- Unity Health Toronto
- Brief Summary
To study whether a diet high in fiber from Konjac-mannan (KJM) has an effect on metabolic control in individuals with insulin resistance syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- Impaired glucose tolerant
- Clinical absent of CHD
- BMI less than 30 kg/m2
- Presence of full insulin resistance syndrome
- Reduced HDL cholesterol
- Elevated serum triglycerides
- Moderate hypertension
Exclusion Criteria
- Regular smoking
- Regular alcohol consumption
- Family history of premature coronary heart disease
- Hypothyroidism
- Renal, hepatic or gastrointestinal disease
- Taking medications for hyperglycemia
- Taking medications for hyperlipidemia
- Taking medications for hypertension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method change in fructosamine change from baseline after 3 weeks, relative to control change in systolic blood pressure change from baseline after 3 weeks, relative to control change in total:HDL cholesterol change from baseline after 3 weeks, relative to control
- Secondary Outcome Measures
Name Time Method change in total cholesterol change from baseline after 3 weeks, relative to control change in LDL cholesterol change from baseline after 3 weeks, relative to control change in glucose change from baseline after 3 weeks, relative to control change in insulin change from baseline after 3 weeks, relative to control change in HDL cholesterol change from baseline after 3 weeks, relative to control change in apolipoprotein A-1 change from baseline after 3 weeks, relative to control change in apolipoprotain B change from baseline after 3 weeks, relative to control change in diastolic blood pressure change from baseline after 3 weeks, relative to control change in body weight change from baseline after 3 weeks, relative to control change in apoB:ApoA-1 change from baseline after 3 weeks, relative to control